Evidence map›Paper›PMID 41279927›Full record

ArticlebioRxiv : the preprint server for biology2025

Chronic pancreatitis patient-derived organoids reveal new paths to precision therapeutics.

Victoria Osorio-Vasquez, Jonathan Zhu, Jan C Lumibao, Kathryn Lande, Kristina L Peck, McKenna K Stamp, Shira R Okhovat, Hyemin Song, Satoshi Ogawa, Casie Kubota and 25 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Victoria Osorio-VasquezSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0001-7956-1633
Jonathan ZhuSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0001-7074-0459
Jan C LumibaoSalk Institute for Biological Studies, La Jolla, CA, USA.
Kathryn LandeSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0009-0005-1613-8981
Kristina L PeckSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0009-0004-7235-2774
McKenna K StampSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0009-0004-1305-9682
Shira R OkhovatSalk Institute for Biological Studies, La Jolla, CA, USA.
Hyemin SongSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-3660-5904
Satoshi OgawaSalk Institute for Biological Studies, La Jolla, CA, USA.
Casie KubotaSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0003-2323-7409
Vasiliki PantazopoulouSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-5965-5795
Yang DaiSalk Institute for Biological Studies, La Jolla, CA, USA.
Angelica RockSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0009-0007-3360-1709
Chelsea BottomleySalk Institute for Biological Studies, La Jolla, CA, USA.
Ethan ThomasSalk Institute for Biological Studies, La Jolla, CA, USA.
Jasper HsuSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0001-8576-1957
Araceli Herrera MoralesSalk Institute for Biological Studies, La Jolla, CA, USA.
Alexandra FowlerSalk Institute for Biological Studies, La Jolla, CA, USA.
T'Onj McGriffSalk Institute for Biological Studies, La Jolla, CA, USA.
K Garrett EvensenSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-6720-2526
Siri LarsenSchulze Diabetes Institute, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA.
Muhamad AbdullaSchulze Diabetes Institute, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA.
Phil GreerAriel Precision Medicine, Pittsburgh, PA, USA.ORCID 0000-0003-2266-4265
Jessica GibsonAriel Precision Medicine, Pittsburgh, PA, USA.
Michael DownesSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-6351-9585
Ronald EvansSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-9986-5965
Andrew M LowyDepartment of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
David C WhitcombAriel Precision Medicine, Pittsburgh, PA, USA.
Jingjing ZouHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, CA, USA.
Alfredo MolinoloDepartment of Pathology, Biorepository and Tissue Technology Shared Resource, Moores Cancer Center, UC San Diego, San Diego, CA, USA.
Tae Gyu OhUniversity of Oklahoma, College of Medicine, Oklahoma City, OK, USA.
Rebekah WhiteDepartment of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
Melena BellinSchulze Diabetes Institute, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA.
Herve TiriacDepartment of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA.ORCID 0000-0001-5039-6750
Dannielle D EngleSalk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0003-1876-7675

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8M
Salk Institute Cancer Training GrantT32CA009370 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Diana Clare Hargreaves, Jan Karlseder · 1986 to 2026
$8.6M
San Diego Nathan Shock CenterP30AG068635 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI SHADEL, GERALD · 2020 to 2024
$6.0M
NCI NIH HHS P30 CA014195NCI NIH HHS P30 CA023100NCI NIH HHS T32 CA009370NIA NIH HHS P30 AG068635
6 · The paper itself

Abstract

Chronic pancreatitis (CP) affects ~3 million people worldwide, yet altering the course of disease is challenging. We developed a patient-derived organoid (PDO) platform to investigate the molecular pathogenesis of this disease and identify therapeutic strategies. We generated 36 PDOs from patients with idiopathic, hereditary, and alcohol-related CP with high genetic concordance. PDOs retained inflammation-associated transcriptional and proteomic features. Transcriptomic profiling revealed three molecular subtypes of CP independent of etiology. We discovered widespread dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) in half of the CP PDOs, including those with wildtype CFTR. Clinically available CFTR modulators stabilized mutant or wildtype CFTR, restored CFTR function, and decreased mitogenic and inflammatory signaling. This work provides the first comprehensive PDO platform for modeling CP. We demonstrate the utility of this platform for precision therapeutic investigations. Our findings reveal CFTR modulators as a broadly applicable and effective therapeutic strategy.

Indexed as

CFTRCFTR correctorsCFTR potentiatorschronic pancreatitismolecular subtypespatient derived organoids

Identifiers

PMID41279927
PMCPMC12633304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.